The computerized tomography (CT) scans of 50 patients with surgically proven subdural hematomas were subdivided into three groups on the basis of the attenuation coefficients of the subdural fluid collections: 28% were more dense, 24% isodense, and 48% less dense than the surrounding brain. The 42 patients with the available data were then subdivided into three groups; acute, subacute, and chronic, according to the time interval between trauma or duration of symptoms and date of CT scanning. Subdural hematomas were found to be hyperdense in 100% of acute patients, isodense in 70% of the subacute group, and hypodense in 76% of the chronic group.
Summary:In this retrospective study, we evaluated the predictability of PBSC dose for hematopoietic engraftment comparing that calculated by ideal body weight (IBW) vs another calculated by actual body weight (ABW) for each patient. Sixty-three consecutive patients treated similarly using one transplant protocol were analyzed. While all patients had data available on CFU-GM and nucleated cells (NC), data on CD34 + enumeration was present only in 34 patients. We found that 49% of the patients were greater than 25% over their IBW. In addition, least-squares linear regression was used to assess the strength of the linear relationship between the inverse of cell dose/kg of ABW or IBW and time to AGC or platelet engraftment and showed no difference in r 2 values for platelet engraftment, while using dose/kg of IBW greatly improved the ability of NC (r 2 improved from 0.19 for ABW to 0.35 for IBW) and CFU-GM (r 2 improved from 0.35 for ABW to 0.53 for IBW) to predict time to AGC engraftment, but did not change the CD34 r 2 . Hazard ratios were estimated using Cox proportional hazards regression and in all instances were found greater than 1.0 indicating that the probability of engraftment increased as cell dose/kg ABW or IBW increased. Finally, our data showed that 10 patients (16%) could have had one less apheresis procedure performed to obtain their set target stem cell dose calculated per kg IBW rather than ABW. In conclusion, PBSC dose per kg IBW is as good or better predictor of engraftment of AGC and may lead to cost savings in a certain subset of patients. Keywords: autologous stem cell transplantation; cell dose; actual body weight; ideal body weight High-dose chemotherapy (HDC) with peripheral blood stem cell (PBSC) rescue is an acceptable form of therapy for high-risk and metastatic breast cancer, relapsed and refractory Hodgkin's or non-Hodgkin's lymphoma, multiple myeloma, and other malignancies. Utilization of HDC with PBSC support has largely replaced bone marrow as the source of autologous hematopoietic stem cells. 1-6 PBSC Correspondence: Dr J Moreb, Division of Hematology/Oncology, PO Box 100277, Gainesville, FL 32610-0277, USA Received 31 July 1998; accepted 2 December 1998 products minimize the chief side-effects of HDC by fast reconstitution of hematopoiesis. In early studies, the PBSC product was evaluated prospectively by total number of nucleated or mononuclear cells and retrospectively by CFU-GM per kilogram of actual body weight, the value of which is known to correlate with days to engraftment of platelets (PLT) and absolute granulocyte counts (AGC). [7][8][9][10][11][12][13][14][15][16] Presently, the stem cell product is characterized in most laboratories by the number of CD34 + , CFU-GM, and total mononuclear cells per kilogram patient actual body weight (ABW). 1,[17][18][19][20] The number of CD34 + cells correlates well with CFU-GM content and serves as a better predictor of engraftment than total mononuclear cells per kilogram of ABW. 21,22 Recent evidence suggests that markers of primi...
This study compares the oral findings in fragile X syndrome individuals to those of normal age-matched patients. Sixteen fra(X) males (mean age 22 10/12 years) had a low caries rate (decayed, missing and filled surfaces (DMFS) = 12.3) and minimal intraoral hard or soft tissue disease. Rate of malocclusion, as determined by the first permanent molar classification of Angle, was not significantly different from that of matched subjects. Fra(X) subjects had a significantly higher occurrence of malocclusion as compared to matched subjects using crossbite and openbite as criteria. Palatal dimensions of fra(X) subjects did not differ significantly from those of the matched sample. The fra(X) males also demonstrated significantly more severe occlusal wear of their teeth than the matched sample.
A combination of cisplatin and cytosine arabinoside was used to treat 21 patients with glioblastomas and 5 patients with recurrent grade II gliomas. Cisplatin 60-100 mg/m2 was given I.V. in 250 ml 0.45% saline and preceded by 500 ml dextrose 5% in 0.45% saline. Mannitol 50 g was given I.V. concurrently with the cisplatin. Cytosine arabinoside 500-1000 mg/m2 was given by rapid I.V. infusion immediately after the cisplatin. Of 25 evaluable patients, 10 (40%) experienced objective tumor shrinkage on CT scan, and 6 (24%) stabilized. There were 2 complete remissions. Patients who had had no prior treatment had a higher response rate (58%) than those previously treated (23%). Myelosuppression occurred in some patients 2-3 weeks after treatment. Gastrointestinal toxicity (vomiting and diarrhea) was dose-limiting. Two patients had possible neurological toxicity. Recommended doses for further studies are cisplatin 90 mg/m2 and cytosine arabinoside 900 mg/m2.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.